Alternatives
A Citeline alternative — when nobody owns the reading.
Citeline sells curated R&D data of real quality. Prognyx sells the conclusion drawn from it, in one therapeutic area. The choice is about which of those you are missing.
People search for a Citeline alternative for reasons that have little to do with the data being wrong. Usually it is one of three: the subscription is sized for an organisation with a research function, the therapeutic breadth is far wider than a single-asset company needs, or there is simply nobody whose week has room for a platform in it.
Prognyx answers the second and third directly, and the first only partly. It is not a cheaper Citeline — it is a different shape of purchase.
What Citeline actually is
Citeline, a Norstella company, publishes a suite of curated pharmaceutical R&D intelligence products. The three most often shortlisted against a service like this one are Pharmaprojects, its drug-pipeline database covering global R&D from discovery to launch; Trialtrove, its clinical-trial intelligence database covering trial design, endpoints, enrolment and outcomes; and Sitetrove, its investigator and site intelligence. Enhanced tiers add analytics such as company comparison, drug similarity and enrolment benchmarking, plus an AI search assistant.
The distinguishing feature is human curation at scale: Citeline states that its data is curated by a large team of therapeutically aligned analysts working across tens of thousands of sources, and subscribers get a direct channel to those analysts through its Ask the Analyst service. That is a genuine capability, and nothing on this page disputes it.
What Prognyx is
Prognyx is not a database. It is an outsourced oncology competitive-intelligence function: one analyst who watches your competitive set continuously and sends briefs on what changed, what it means for your asset and what to do about it — every claim traced to the primary record.
| Dimension | Citeline | Prognyx |
|---|---|---|
| What you buy | A subscription to curated R&D databases — Pharmaprojects (pipeline), Trialtrove (trials), Sitetrove (sites and investigators) | A person’s output — the watch, the analysis and the recommendation |
| Who does the analysis | Your team, inside the platform — with Ask the Analyst available for questions | Prognyx, before it reaches you |
| Therapeutic coverage | All of pharma and medtech, every indication | Oncology only, deliberately |
| Curation model | A large in-house team of therapeutically aligned analysts curating from tens of thousands of sources | One named analyst reading a narrow landscape continuously |
| Delivery | A login, with saved searches and alerting you configure | A brief. It comes to you |
| Best case | A team benchmarking trial design, feasibility or site selection at volume | A CBO or CMO with a competitor readout and no analyst |
| Seats | Priced and provisioned per seat and per product | Not applicable — the deliverable is forwardable |
| Contract shape | Typically annual, enterprise procurement | Month to month, written scope, no lock-in |
| Accountability for a wrong read | The read is yours — the platform supplied curated data | One named analyst, publicly |
| Published pricing | Not published | Published — from $2,000/mo |
When Citeline is the better buy
Straightforwardly, and without hedging:
- You are designing or benchmarking trials. Trialtrove is built for exactly that — comparing endpoints, inclusion criteria, enrolment timelines and design choices across a large historical trial set. Prognyx does not hold that dataset and cannot substitute for it.
- You need site and investigator selection. Sitetrove has no analogue here at all. If feasibility and site strategy are the question, this is not a close call.
- You need coverage beyond oncology. Prognyx covers oncology only and will decline the rest rather than cover it thinly.
- You want a queryable pipeline you can export. Pharmaprojects gives you rows to filter, sort and drop into your own models. A brief is prose.
- You have analysts. If someone's job title contains "competitive intelligence", they need a data environment, and Prognyx does not provide one.
When Prognyx is the better buy
- The work currently happens at 11pm. Curated data still has to be read by someone. If competitive intelligence is an evening task for your CBO or CMO, another login does not create the hours.
- Your competitive set is narrow and deep. Two assets, a defined mechanism, a handful of named rivals with dates attached. Industry-wide curation is capacity you would pay for and not use.
- You need the implication, not the record. Knowing that a rival amended its primary endpoint is the easy half. Knowing what that does to the bar you will be measured against is the job.
- Silence is what you keep missing. A trial that quietly stopped enrolling, a completion date pushed twice, a programme dropped from a pipeline page. Nothing announces an absence; it is only visible if someone compares this month's record to last month's.
- You want someone accountable. A database supplies data; if the read is wrong, the read was yours. Here it is Rali Filali's, by name.
The cost question, honestly
Citeline does not publish list pricing, and this page will not invent a number for it. What can be said about the shape: enterprise R&D intelligence suites are licensed per product and per seat, on annual terms, through a procurement cycle — a structure designed for organisations that will use several modules across several teams.
For a company with one lead asset, the comparison that matters is not licence versus retainer. It is the total cost of reaching a decision, senior hours included. Prognyx publishes its floor: from $2,000/mo, scoped to your pipeline.
Using both
They compose. A company that already licenses Pharmaprojects or Trialtrove for trial design work sometimes brings in Prognyx for continuous depth on the one or two assets that determine the company's value, while the platform keeps serving the broad questions. Nothing here requires you to cancel anything.
How to decide in one question
Ask what you would do with the data on the day it arrives. If the answer is "run a benchmarking analysis", buy the database. If the answer is "someone would have to read it and tell us what it means", you are describing a person, not a subscription.
Comparison last reviewed 1 September 2026. This page describes Citeline from its public product information and does not claim to be exhaustive; Citeline does not publish list pricing, and nothing here invents any. Prognyx has no affiliation with Citeline. Verify current scope and pricing with the vendor directly before any purchase decision. Names and trademarks referenced belong to their owners.
Frequently asked
What is the best Citeline alternative for a small oncology biotech?
It depends on which half is missing. If you need curated pipeline and trial data your team will query — Trialtrove and Pharmaprojects equivalents — the alternatives are other platforms in the category (Cortellis, GlobalData, Beacon). If what you lack is the analyst rather than the data, the alternative is a delivered service: Prognyx does oncology competitive intelligence from $2,000/mo, with the reading already done.
Is Prognyx cheaper than Citeline?
Citeline pricing is not public, so no honest direct comparison is possible and this page will not fabricate one. Prognyx publishes its own floor — $2,000/mo — positioned for companies with one lead asset and no CI department. They are also not substitutes: one licenses curated data, the other delivers finished analysis.
Can Prognyx replace Trialtrove or Pharmaprojects?
Not for trial benchmarking, feasibility or pipeline export — those are dataset capabilities Prognyx does not have. It can replace the expectation that someone will find time to mine a dataset, which is a different and much more common failure.
Does Prognyx use Citeline data?
No. Prognyx holds no paid-database licence. It works from primary public records — ClinicalTrials.gov, SEC filings, FDA and EMA actions, peer-reviewed literature and congress abstracts — and cites each one so you can open it. See how we work.
Compare the output, not the brochures.
Name one asset you'd want watched. You get a real competitive brief on it — free, sourced, no obligation. Then judge.
Request a sample brief → See a sample first